Bicara Therapeutics
bicara.com
Actively hiring
Health Care
Pharmaceuticals
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to brin...
Read more
Report
Bicara TherapeuticsAnnounces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective August
Read more
Report
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.
Read more
Report
ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: FORTIFI-HN01
The post ASCO 2026 Poster Presentation: A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squ
Read more
Report
ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)
The post ASCO 2026 Poster Presentation: The impact of depth of response on long-term clinical outcomes: Exploratory analyses from multiple expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent/metastatic (R/
Read more
Report
Pro access
Upgrade to see all 19 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Technologies
Tech DNA
GCP
Security
CAPA
Other
GCP
Microsoft Excel
Smartsheet
Stack modernity
43/100
How modern this stack is, based on technology relevance, AI adoption and the share of legacy tools.
In-demand technologies
GCP
2 jobs
Required
$216k
+8% vs market
Microsoft Excel
1 job
Optional
$226k
+126% vs market
CAPA
1 job
Required
$197k
+33% vs market
Salary medians are calculated from this company's open jobs and compared with the market.
Industry adoption
GCP
4%
Microsoft Excel
4%
Smartsheet
1%
CAPA
1%
Share of companies in the same industry that use each technology.
Stack changes
Smartsheet
Sep 2026
Microsoft Excel
Sep 2026
GCP
Sep 2026
CAPA
Sep 2026
Technologies recently added to or removed from this company's stack - a signal of tech migrations and new initiatives.
Natera
Everpure
Analog Devices
Axon Enterprise
ResMed
Amgen
Salary insights
Compensation ranges based on this company's open jobs
Median
$236k
Typical range
$151k – $368k
Open positions
12
12
Jobs
Senior
41.7%
Staff
8.3%
Architect
50%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 5 | $206k | $151k – $331k |
| Staff | 1 | $197k | $197k |
| Architect | 6 | $252k | $226k – $368k |
Highest paying role
Executive Director, Trade Relations
$368k
Normalized to USD per year
Growth
Hiring Momentum
65/100
Growing
Open positions
12
3 opened / 3 closed in 30 days
Median time-to-fill
91 days
faster than 19% of the market
ATS activity
Every ~2 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Finance
33% ▼
Legal
17% ▲
Operations
17% ▼
Field & Service
17% ▼
Marketing
8% ▲
Sales
8% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Boston
Boston
United States
Sales office
7 open roles 8 posted in 90 days 50-200 est. staff $230k Avg Salary
hires for Finance, Marketing, Sales